Contact PI/Project LeaderMARRUS, NATASHA Other PIs
Awardee OrganizationWASHINGTON UNIVERSITY
Description
Abstract Text
ABSTRACT
Down syndrome (DS), the most common genetic cause of intellectual disability, accounts for ~30% of all
moderate-to-severe IDD cases, with ~5,500 new individuals diagnosed with DS each year in the United States.
DS is associated with varying degrees of cognitive impairment from infancy onward, yet progress has been very
limited in understanding the relationships between neurodevelopment in DS and deficits in function. While clear
structural brain differences and altered functional connectivity have been observed in DS at older ages, limited
knowledge of infant brain development in DS hampers understanding of the relationship between brain
differences and early delays, as well as the impact of disrupted development of neurocircuitry on later function.
Infant brain imaging studies are needed to clarify mechanisms that could guide novel interventions during a
highly plastic stage of neurodevelopment and to identify biomarkers that could inform the personalization of DS
treatment and enhanced outcomes. In-depth characterization of DS-associated developmental differences in
neural circuit structure and function is also key to evaluating a range of emerging pharmacologic therapies and
genetic modulators that show promise for improving long-term function.
To address these gaps, our team proposes to complete deep phenotyping and neuroimaging in a DS
infant cohort in response to RFA-OD-24-003, which articulates the plan for multiple sites to collaboratively
assemble a lifespan cohort of individuals with DS. Here we propose to leverage the Infant Brain Imaging Study
Network (IBIS), a multisite, multidisciplinary team with >15 years’ experience in infant recruitment and collection
of longitudinal behavioral and neuroimaging data in typically developing infants and infants with Autism spectrum
disorder (ASD), DS, and Fragile X Syndrome. Our specific aims are: 1) To collect multimodal neuroimaging,
including structural and functional MRI, as well as EEG, in a cohort of 100 infants with DS and 50 typically
developing controls at ages 6, 12, and 24 months; 2) to perform concurrent, longitudinal deep phenotyping on
these infants in key developmental domains of cognition and adaptive function, and 3) to collect data
characterizing variation in early social communication in these infants that would advance early risk assessment
for ASD, which occurs in ~15% of children with DS. Our team will leverage IBIS’ expertise in ASD-relevant
phenotyping to include standardized clinical measures as well as dimensional research measures allowing more
refined characterization of social attention and language. Data will be collected on medical comorbidities,
sociodemographic information, and family environmental factors, along with biospecimens for future genetic
analyses. Data will be accessible to the scientific community and allow novel analyses to characterize the nature
and timing of altered neurodevelopment in DS, as well as establish a richly phenotyped cohort for future
longitudinal studies elucidating relationships between infant brain and behavioral development and long-term
outcomes.
Public Health Relevance Statement
NARRATIVE
Down syndrome (DS) is the most common genetic cause of intellectual disability, yet progress has been very
limited in understanding how early brain development in DS relates to long-term functional outcomes. In this
project, the Infant Brain Imaging Study, a team with over 15 years’ of experience in infant neuroimaging, will
collect comprehensive, state-of-the-art brain and behavioral data in infants with DS at ages 6, 12, and 24
months, with collection at five clinical sites across the U.S. These data will allow identification and tracking of
early brain differences in DS and their relationships to behavior, which can help guide intervention research
aimed at improving developmental outcomes.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
068552207
UEI
L6NFUM28LQM5
Project Start Date
20-September-2024
Project End Date
31-May-2029
Budget Start Date
20-September-2024
Budget End Date
31-May-2026
Project Funding Information for 2024
Total Funding
$2,927,457
Direct Costs
$2,638,654
Indirect Costs
$288,803
Year
Funding IC
FY Total Cost by IC
2024
NIH Office of the Director
$2,927,457
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1U01HD116463-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U01HD116463-01
Patents
No Patents information available for 1U01HD116463-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U01HD116463-01
Clinical Studies
No Clinical Studies information available for 1U01HD116463-01
News and More
Related News Releases
No news release information available for 1U01HD116463-01
History
No Historical information available for 1U01HD116463-01
Similar Projects
No Similar Projects information available for 1U01HD116463-01